

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau**B24**

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, 7/04	A1	(11) International Publication Number: WO 97/21728 (43) International Publication Date: 19 June 1997 (19.06.97)
(21) International Application Number: PCT/SE96/01621 (22) International Filing Date: 9 December 1996 (09.12.96) (30) Priority Data: 9504467-3 12 December 1995 (12.12.95) SE 60/009,386 29 December 1995 (29.12.95) US (71) Applicant (for all designated States except US): KAROLIN- SKA INNOVATIONS AB [SE/SE]; Karolinska Institutet, S-171 77 Stockholm (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): NORDSTEDT, Chris- ter [SE/SE]; Nora Torg 37, S-118 34 Danderyd (SE). NÄSLUND, Jan [SE/SE]; c/o Larsson, Banérgatan 55, S-115 53 Stockholm (SE). THYBERG, Johan [SE/SE]; Karlavägen 47B, S-114 49 Stockholm (SE). TJERNBERG, Lars, O. [SE/SE]; Pumpbrinken 1A, S-163 56 Spånga (SE). TERENIUS, Lars [SE/SE]; Kyrkogårdsgatan 27, S-753 12 Uppsala (SE). (74) Agent: AWAPATENT AB; P.O. Box 45086, S-104 30 Stockholm (SE).		(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID β (57) Abstract <p>The invention relates to compounds of formula (I) or (II), which are of interest especially for inhibition of polymerization of amyloid β peptide, as model substances for synthesis of amyloid β peptide-ligands, as tools for the identification of other organic compounds with similar functional properties and/or as ligands for detection of amyloid deposits using e.g. positron emission tomography (PET). Formula (II) is: $R_1 - A' - Y' - Leu - X' - Z' - B' - R_2$, in which X' means any group or amino acid imparting to the compound according to formula (I) the ability to bind to the KLVFF-sequence in amyloid β peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline; Y' means any amino acid; Z' means any non-acidic amino acid; A' means a direct bond or an α-amino acid bonded at the carboxyl terminal of the α-carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α-carboxy group; B' means a direct bond or an α-amino acid bonded at the α-nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α-nitrogen of the N-terminal α-amino acid; R_1 is H or $-CO-R_3$ bonded at the α-aminogroup of A'; R_2 is H, $-OR_4$ or NR_5R_6, all bonded to the α-carboxyl group of the α-carboxyterminal of B'; R_3 and R_4 are straight or branched carbon chain of 1-4 carbon atoms; R_5 and R_6 are independently H, alkyl, cycloalkyl, aryl or substituted aryl or together are $-(CH_2)_n-$, where n is 4-5; and R_1 and R_2 together can form a hydrocarbon ring or heterocyclic ring; all α-amino acids being either D- or L-isomers.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID- β

Introduction

5 The present invention relates to compounds,
which are of special interest by their ability to
bind to the KLVFF-sequence in the peptide amyloid β
and to inhibit polymerization of the amyloid β
peptide. The compounds according to the invention are
10 e.g. useful as medicaments and as tools for identification of substances to be used in the treatment or prevention of amyloidosis.

Background of the invention

15 Amyloidosis is a condition which is
characterized by the deposition of amyloid in organs
or tissues of the human or animal body, either as a
primary disease of unknown cause or secondary to
chronic disease, such as tuberculosis or osteomyeli-
20 tis. In addition, it has also been found that the
pre-eminent neuropathological feature of Alzheimer's
disease (AD), a chronic condition of brain atrophy,
is the deposition of amyloid in the brain parenchyma
and cerebrovasculature (D.J. Selkoe, *Neuron* 6,
25 487-498 (1991); D.J. Selkoe, *Annu. Rev. Cell Biol.*
10, 373-403 (1994)).

 The basic component of such amyloid is a peptide
termed amyloid β , or A β (G.C. Glenner, C.W. Wong,
Biochem. Biophys. Res. Commun. 120, 885-890 (1984)).
30 It is a 40 to 42 amino acids long proteolytic frag-
ment of the Alzheimer amyloid precursor protein
(APP), a protein expressed in most tissues (J. Kang,
et al., *Nature* 325, 733-736 (1987)). Genetic and
neuropathological studies provide strong evidence for
35 a central role of A β in the pathogenesis of AD, but
the pathophysiological consequences of the amyloid

deposition are still unclear. However, it has been suggested that A β polymers and amyloid are toxic to neurons, either directly or indirectly, and hence cause neurodegeneration (C. Behl, J. B. Davis, R. Lesley, D. Schubert, *Cell* 77, 817-827 (1994); D.T. Loo, et al., *ibid* 90, 7951-7955 (1995)).

The amyloid associated with Alzheimer's disease (AD) consists of thin fibrils of polymerized A β . A rational pharmacological approach for the prevention of amyloidogenesis would therefore be to use drugs that specifically interfere with A β -A β interaction and polymerization. Previous studies showed that A β polymerization *in vivo* and *in vitro* is a highly specific process, which probably involves an interaction between binding sequences in the A β peptide (J. Näslund, et al., *Proc. Natl. Acad. Sci. USA* 91, 8378-8382 (1994); J. Näslund, et al., *Biochem. Biophys. Res. Commun.* 204, 780-787 (1994)).

Wood et al (S.J. Wood, R. Wetzel, J.D. Martin, M.R. Hurle, *Biochemistry* 34, 724-730 (1995)) suggest that amino acid residues within or close to A β -16-20 are important for the adoption of the correct β -pleated sheet structure of A β and show that amino acids 17-23 in the amyloid β peptide (A β) are essential for fibril formation and probably make up the β -sheet core of the fibrils. In addition, Wood et al. have investigated the ability of their peptides to form amyloid fibrils in a solution containing solely the mutated or the wild-type peptide. However, no method or principle which makes it possible to inhibit A β of wild type from forming amyloid fibrils is devised and no use of the peptides as medicaments is suggested.

WO 95/08999 relates to amelioration of amnesia in Alzheimer's disease caused by deposition of amyloid β protein. Three peptides are disclosed, which overcome the amnestic effects of β -12-28, a peptide

homologous to A β . In addition, WO 95/08999 describes the screening of several other peptides, which were neither significantly amnestic nor memory enhancing, of which one is KLVFF, SEQ. NO. 15 of the sequence listing therein.

In EP 0 584 452, novel amyloid precursor proteins and the sequences thereof are disclosed. Peptide sequences that comprise KLVFF are revealed. However, neither binding to amyloid β peptide nor any inhibition of the polymerization thereof is suggested.

Summary of the invention

Thus, the polymerization of the amyloid β peptide (A β) into amyloid fibrils is a critical step in the pathogenesis of Alzheimer's disease.

In vitro and *in vivo* studies of A β have shown that the A β molecules interact with a high degree of specificity during polymerization and fibril formation. It was assumed that ligands which bind to recognition sequences would be capable of inhibiting A β polymerization and possibly also dissolve pre-formed A β polymers *in situ*. The strategy in finding such A β ligands was to identify critical binding regions in A β and, based on their sequences, develop a compound capable of blocking the A β -A β binding.

According to the invention, it was hypothesized that compounds capable of binding to regions in the A β -molecule critical for its polymerization might inhibit amyloid fibril formation, as described in more detail below.

According to the invention, it has now been found that the Lys-Leu-Val-Phe-Phe (KLVFF) sequence in A β is necessary for polymerization to occur. Peptides incorporating this sequence bind to A β and are capable of blocking the fibril formation of A β -1-40 and are therefore potentially useful as drugs.

In addition, compounds have been found, which

- 1) are capable of binding to full-length A β ,
- 2) are capable of blocking A β fibril formation and
- 3) do not form fibrils by themselves.

5 In addition, it has also been found that alanine-substituted A β -1-28 (Ala at position 16,17,20), in contrast to wild-type A β -1-28, does not form fibrils.

Thus, it was concluded that the Lys-Leu-Val-Phe-
10 Phe (16-20) motif serves as a structural basis for the development of peptide and non-peptide agents aimed at inhibiting amyloidogenesis *in vivo*. This is a novel finding and the compounds are of utmost interest as being useful as drugs for Alzheimer's
15 disease.

Further, the findings according to the invention are even more surprising on the basis of what was concluded from WO 95/08999 mentioned above. In WO 95/08999, it was concluded that KLVFF is not a poten-
20 tial candidate for the development of substances that can antagonize binding of A β and thus attenuate symptoms and progression of AD. Even though the teaching of said WO publication indicates the opposite, according to the present invention, it has now been
25 found that KLVFF on the contrary is most useful for the development of new compounds defined by Formula (I) and (II) below.

Detailed description of the invention

30 The present invention relates to compounds which are able to bind to the Lys-Leu-Val-Phe-Phe-sequence, or KLVFF-sequence, in the peptide amyloid β . More specifically, the compounds according to the invention are defined by their formula (I):


35 $R_1 - A' - Y' - \text{Leu} - X' - Z' - B' - R_2$ (I)
in which

- X' means any group or amino acid imparting to the compound of formula (I) the ability to bind to the KLVFF-sequence in amyloid β peptide, or two amino acids imparting the same ability, but with the proviso that one is
- 5 not proline;
- Y' means any amino acid;
- Z' means any non-acidic amino acid;
- A' means a direct bond or an α -amino acid bonded at the carboxyl terminal of the α -carboxy group or a di-, tri-,
- 10 tetra- or pentapeptide bonded at the carboxyl terminal of the α -carboxy group;
- B' means a direct bond or an α -amino acid bonded at the α -nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α -nitrogen of the N-terminal α -amino acid;
- 15 R₁ is H or -CO-R₃ bonded at the α -amino group of A';
- R₂ is H, -OR₄ or NR₅R₆, all bonded to the α -carboxyl group of the α -carboxyterminal of B';
- R₃ is a straight or branched carbon chain of 1-4 carbon atoms;
- 20 R₄ is a straight or branched carbon chain of 1-4 carbon atoms;
- R₅ and R₆ independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are -(CH₂)_n-, where n is 4-5;
- R₁ and R₂ together can form a hydrocarbon ring or
- 25 heterocyclic ring; and
- all the α -amino acids can be either D- or L-isomers; with the proviso that (I) is not Lys-Leu-Val-Phe-Phe.
- With alkyl is preferably meant a chain of 4 or less carbon atoms, e.g. methyl, ethyl, propyl or
- 30 butyl.
- With cykloalkyl is preferably meant a ring of 3, 4, 5 or 6 carbon atoms.
- Aryl preferably means a phenyl group, which can be substituted, preferably by a methyl, ethyl, propyl
- 35 or butyl group, an amino or a methoxy, ethoxy, propoxy or butoxy group.

In a preferred embodiment of the present invention, the compound exhibits an ability to inhibit polymerization of amyloid β peptide.

In one embodiment of the invention, all the amino acids of the compound are D-isomers.

In one embodiment of the invention, Y' is Lys, and in a particular embodiment of the invention, Z' is Phe, resulting in a compound of the following formula:




In an alternative embodiment of the invention, Y' is Phe.

Preferred are compounds, wherein X' is Val-Val.

In one embodiment of the present aspect of the invention, R₁ is acetyl.

In an alternative embodiment of the invention, R₁ is H. According to another embodiment, R₂ is H. Alternatively, R₁ and R₂ are both H.

A second aspect of the present invention is the use of a compound of formula:



in which

X' means any group or amino acid imparting to the compound of formula (II) the ability to bind to the KLVFF-sequence in amyloid β peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline;

Y' means any amino acid;

Z' means any non-acidic amino acid;

A' means a direct bond or an α -amino acid bonded at the carboxyl terminal of the α -carboxy group or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α -carboxy group;

B' means a direct bond or an α -amino acid bonded at the α -nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α -nitrogen of the N-terminal α -amino acid;

R_1 is H or $-\text{CO}-R_3$ bonded at the α -amino group of A' ;
 R_2 is H, $-\text{OR}_4$ or NR_5R_6 , all bonded to the α -carboxyl group of the α -carboxyterminal of B' ;

5 R_3 is a straight or branched carbon chain of 1-4 carbon atoms;

R_4 is a straight or branched carbon chain of 1-4 carbon atoms;

R_5 and R_6 independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are $-(\text{CH}_2)_n-$ where n is 4-5;

10 R_1 and R_2 can together form a hydrocarbon ring or heterocyclic ring; and

all the α -amino acids can be either D- or L-isomers; for inhibition of polymerization of amyloid β peptide, as a model substance for synthesis of amyloid β peptide-ligands for inhibition of polymerization of amyloid β peptide, as a tool for the identification of other organic compounds with similar functional properties or as ligand for detection of amyloid deposits using e.g. positron emission tomography (PET).

15 20 With alkyl is preferably meant a chain of 4 or less carbon atoms, e.g. methyl, ethyl, propyl or butyl.

With cycloalkyl is preferably meant a ring of 3, 4, 5 or 6 carbon atoms.

25 Aryl preferably means a phenyl group, which can be substituted, preferably by a methyl, ethyl, propyl or butyl group, an amino or a methoxy, ethoxy, propoxy or butoxy group.

30 In one embodiment of this second aspect of the invention, a compound is used, wherein all the amino acids are D-isomers.

In a particular embodiment of this aspect of the invention, Y' is Lys. A particular embodiment is when Z' is Phe, resulting in a compound of the following formula:

35 $R_1-A'-\text{NH}-\text{CH}[(\text{CH}_2)_4-\text{NH}_2]-\text{CO}-\text{Leu}-X'-\text{NH}-\text{CH}[-\text{CH}_2-\text{Ph}]-\text{CO}-B'R_2.$

In an alternative embodiment, a compound is used, wherein Y' is Phe while Z' is any non-acidic amino acid.

In a preferred embodiment of this aspect of the invention, a compound is used, wherein X' is Val-Val.

In one embodiment of the use according to the invention, R₁ is acetyl. Alternatively, R₁ and/or R₂ are H.

Yet another aspect of the present invention is a compound according to the invention for use as a medicament.

Also claimed is the use of a compound, preferably of the formula (I) or (II), which is able to bind to the KLVFF-sequence in amyloid β peptide and which has the ability to inhibit polymerization of amyloid β peptide, for the manufacture of a medicament for the treatment or prevention of amyloidosis, especially in the treatment or prevention of Alzheimer's disease associated with amyloidosis, for the treatment or prevention of demens in patients with Down's syndrome, for the treatment or prevention of Hereditary cerebral hemorrhage with amyloidosis (Dutch type) or for the prevention of fibril formation of human amyloid protein.

Further, a last aspect of the present invention is a composition comprising a compound according to formula II and optionally a ligand capable of binding or interacting with the compound according to formula II and a carrier.

Said composition can e.g. be adapted for injection in a liquid carrier or for oral administration in a tablet or capsule.

Carriers are known for persons skilled in the art.

For clarification the following definitions are given:

K is lysine (Lys), L is leucine (Leu), V is valine (Val), F is phenylalanine (Phe), A is alanine (Ala) and E is glutamic acid (Glu).

As used herein, "any group giving the compound according to formula (I) the ability to bind to the KLVFF-sequence in the amyloid β peptide" means that this group gives the compound a structure, which can fulfil the requirements given in claim 1.

The hydrocarbon ring or heterocyclic ring has preferably 4-6 atoms, preferably C, N and S.

Description of the figures

Fig. 1 A and B. A β -amyloid polymerization.

Fig. 2A. Ten-mers corresponding to consecutive sequences of A β -1-40. Radioactivity bound to the filter was detected by autoradiography and quantified by densitometry.

Fig. 2B. EVHHQ**KLVFF** and N and C-terminal truncated fragments were synthesized and analyzed for affinity to ^{125}I -labelled A β -1-40.

Fig. 2C. Each amino acid residue in KLVFF was systematically replaced with Ala and analyzed for affinity to ^{125}I -labelled A β -1-40.

Fig 2D. Sensorgram from surface plasmon resonance spectroscopy (BIAcore 2000).

Fig. 3 A and B. Content of non-aggregated peptide in the supernatants from incubations of wild-type and Ala-substituted A β -1-28 as analyzed by HPLC.

30 EXPERIMENTAL

Example 1

a) Ten-mers corresponding to consecutive sequences of A β -1-40 were synthesized on a filter matrix using the SPOT-technique (the peptides were synthesized essentially as described by Frank [R. Frank, *Tetrahedron* 42, 9217-9232 (1992)]. Briefly, a spacer corresponding to 2 molecules of β -alanine was coupled to cellu-

lose membranes (Whatman 1Chr). The peptides were synthesized on these derivatized membranes using Fmoc protected and pentafluorophenyl-activated amino acids (AMS Biotechnology) dissolved in N-methylpyrrolidone.

5 Coupling efficiency was monitored using bromphenol blue.). We synthesized the thirty-one possible 10-mers of the A β -1-40. Peptide no. 1 corresponds to amino acids 1-10, peptide no. 2 to amino acids 2-11 etc. The filter-bound peptides were incubated with

10 radioactive A β -1-40. Following washing of the filter in high-salt buffer, bound radioactivity was estimated by autoradiography and densitometry. Following blocking with 0.05% Tween-20 in Tris-buffered saline (TBS), the filter was incubated in the presence of 20

15 μ M 125 I-labelled A β -1-40 at 20°C for 12 h in TBS, pH 7.3, supplemented with 1% bovine serum albumin. The filter was then washed repeatedly in the same buffer containing 0.5 M NaCl and dried. Radioactivity bound to the filter was visualized by autoradiography and

20 quantitated using a densitometer.

b) Peptide no. 11 (EVHHQ**KLVFF**) and indicated N- and C-terminal truncated fragments were synthesized using the same technique as described above and analyzed for affinity to 125 I-labelled A β -1-40.

25 c) Sensorgram from BIAcore 2000. A β -1-40, at three different concentrations in running buffer, pH 7.4. A β -1-40 was injected during 10 minutes over a sensor-chip derivatized with the peptide KLVFF- β A- β A-C.

d) Each amino acid residue in KLVFF was systematically replaced with A and analyzed for affinity to

30 125 I-labelled A β -1-40. Non-specific interactions have been compensated for by subtracting the signal from a surface derivatized with C alone.

35 Results

a) The measured binding should be interpreted as semiquantative, since the coupling efficiency and

therefore the amount of peptide per spot may vary. A region located in the central part of A β (A β -9-18 to A β -13-22) displayed prominent binding of radioactive A β -1-40. Another binding region was the hydrophobic C-terminus of the molecule (D. Burdick, et al, *J. Biol. Chem.* 267, 546-554 (1992)) but binding here was considerably weaker (Fig 2A).

b) Being located in the centre of the binding region, peptide no. 11 (corresponding to A β -11 - 20) was selected for further studies. This peptide, as well as N- and C-terminal fragments thereof, were synthesized using the same technique as described previously. The shortest peptide still displaying high A β binding capacity had the sequence KLVFF, corresponding to amino acids 16-20 of A β (Fig. 2B). By systematically substituting the amino acid residues in the KLVFF sequence with alanine, we found that the first, second and fifth residues (i.e. KLXXF) were critical for binding (Fig. 2C).

c) The interaction between soluble A β -1-40 and immobilized KLVFF was monitored in real-time (Fig. 2D) using surface plasmon resonance spectroscopy (BIAcore, Pharmacia) (BIAcore 2000 (Pharmacia Biosensor AB, Sweden) was used for real-time studies based on surface plasmon resonance spectroscopy. The peptide was immobilized using thiol coupling. The running buffer consisted of 10 mM HEPES, 0.15 M NaCl, 3.4 mM EDTA and 0.05% surfactant P20 as described. [U. Jansson, M. Malmqvist, *Adv. Biosens.* 2, 291-336 (1992)]). The binding was not saturable, indicating that A β -1-40 bound to immobilized KLVFF could interact with other A β -1-40 molecules in a polymerization reaction.

d) AA served as linker between the active peptide and the chip (upper trace) and cysteine alone, indicating non-specific binding, (C) as control (lower

trace). Arrows indicate start and stop of injection (Fig. 2D).

Example 2

5 To investigate if the KLXXF motif was required for A β polymerization, we synthesized A β -1-28, a well-studied A β fragment that readily forms amyloid fibrils (D.A. Kirschner, et al., *Proc. Natl. Acad. Sci. USA* 84, 6953-6957 (1987); C.J. Barrow, M.G. Zagorski, *Science* 253, 179-82 (1991); C. Nordstedt, et al., *J. Biol. Chem.* 269, 30773-30776 (1994)) and mutated A β -1-28 where the KLVFF sequence was substituted with **AAVFA** (A β -1-28**AAVFA**).

15 A β -1-28 (Fig. 3 A) and A β -1-28**AAVFA** (Fig. 3 B) were incubated at 200 μ M in TBS for 24 h at 37°C in a shaking water bath. After incubation, the tubes were centrifuged at 20,000g for 20 min and the content of non-aggregated peptide in the supernatants (Fig. 3 A, B) was analyzed using an established C4 RPLC system (12) whereas the aggregated peptides in the pellets were analyzed by electron microscopy after adsorption to formvar-coated grids and negative staining with 2% uranyl acetate in water.

Results

25 Following incubation at a concentration of 200 μ M for 24 h at 37°C, A β -1-28 aggregated (Fig. 3A) and formed large fibril bundles, whereas A β -1-28**AAVFA** almost completely failed to aggregate (Fig. 3B) and 30 only formed a few dispersed fibrils.

Example 3

A β -1-40 was incubated at 100 μ M in TBS for 48 h at 37°C in a shaking water bath, either alone or together 35 with 100 μ M AcKLVFFNH₂. The polymerized material was adsorbed to formvar-coated grids and negatively stained with 2% uranyl acetate in water.

Results

Incubation of synthetic A β -1-40 at 100 μ M for 48 h at 37°C in a physiological buffer led to polymerization and formation of amyloid fibrils arranged in parallel in densely packed bundles, as previously shown (C. Nordstedt, et al., *J. Biol. Chem.* 269, 30773-30776 (1994)). When A β -1-40 was coincubated with AcQKLIVFFNH₂ at equimolar concentrations, this type of fibrils did not form. Instead, only a few occasional fibrils embedded in a diffuse background of small rod-like aggregates, similar to those formed by AcQKLIVFFNH₂ itself, could be detected.

Example 4

The peptides were synthesized essentially as described by Frank (Frank R, 1992, Tetrahedron 42:9217-9232). Briefly, a spacer corresponding to 2 molecules of β -alanine was coupled to cellulose membranes (Whatman XX). The peptides were synthesized on these derivatized membranes using Fmoc protected and pentafluorophenyl-activated amino acids (AMS biotechnology) dissolved in N-methylpyrrolidone. Coupling efficiency was monitored using bromphenol blue.

Results

The KLXXF motif in the A β molecule is not only critical for polymerization and fibril formation. During non-amyloidogenic processing of APP, the molecule is cleaved between amino acid residues K¹⁶ and L¹⁷ (F.S. Esch, et al., *Science* 248, 1122-1124 (1990)), leading to the formation of a fragment of A β termed p3 and corresponding to A β -17-40 or A β -17-42 (C. Haass, A.Y. Hung, M.G. Schlossmacher, D.B. Teplow, D. J. Selkoe, *J. Biol. Chem.* 268, 3021-3024 (1993)). Through this metabolic pathway the present binding sequence is disrupted. This may explain why

p3 is not capable of forming amyloid *in vitro* or *in vivo* (J. Näslund, et al., *Proc. Natl. Acad. Sci. USA* 91, 8378-8382 (1994); J. Näslund, et al., *Biochem. Biophys. Res. Commun.* 204, 780-787 (1994)). The
5 KLXXF motif is highly sequence specific. The most apparent example of this is the finding that substitution of a single amino acid leads to virtually complete loss of A β binding capacity.

10 Example 5

In an additional series of experiments, it was demonstrated that KLVFF binds stereo specifically to the homologous sequence in A β (i.e. A β -16-20). By screening combinatorial pentapeptide libraries exclusively composed
15 of D-amino acids (lowercase) with labelled KLVFF, several ligands with a motif containing phenylalanine (f) in the second and leucine (l) in the third position were identified (e.g. lflrr). By using a short peptide in the screening, known to bind to a region in A β critical for its
20 polymerization (i.e. KLVFF), the risk of identifying D-pentapeptides that interact with nonrelevant regions in A β (N- or C-terminal to A β -16-20) was eliminated. Like KLVFF, the D-amino acid ligands were found not only to bind to A β but also to inhibit amyloid fibril formation.
25 Since peptides built up of D-amino acids are resistant to proteolytic degradation, these ligands may be beneficial for inhibition of amyloidogenesis *in vivo*. The results further indicate that KLVFF will be useful in the identification of small organic molecules (e.g. by screening of
30 substance libraries) with the ability to bind to A β in this relevant region and inhibit amyloid fibril formation (candidate drugs for the treatment of Alzheimer disease and other related amyloidoses).

Discussion and conclusion

Previous studies of putative inhibitors of amyloid fibril formation showed that cyclodextrins (P. Camilleri, N.J. Haskind, D.R. Howlett, *FEBS Lett.* 341, 256-258 (1994)) and Congo red (A. Lorenzo, B. Yankner, *Proc. Natl. Acad. Sci. USA* 91, 12243-12247 (1994)) may have such properties. The usefulness of these molecules as lead or model substances in development of anti-Alzheimer amyloid drugs is, however, compromised by their relative lack of specificity. Cyclodextrins have primarily been used to increase the solubility of a wide range of lipophilic drugs and it is unlikely that they would display any specificity for A β *in vivo*. Congo red, which is used in histochemistry to detect amyloid, binds to a wide array of non-A β amyloids as well as to other proteins with a high content of β -pleated sheet structures (W.G. Turnell, J.T. Finch, *J. Mol. Biol.* 227, 1205-1223 (1992)).

Due to the extreme insolubility of amyloid, strong chaotropic agents or potent organic solvents are required for its dissolution (C.L. Masters, et al., *Proc. Natl. Acad. Sci. USA* 82, 4245-4249 (1985)), the concept of dissolving amyloid deposits *in situ* under physiological conditions may seem futile. However, the bulk of the individual molecules in amyloid are probably not joined by covalent bonds and the deposition of A β into amyloid is, at least at some stages, a dynamic and reversible process (J.E. Maggio, et al., *ibid.*, 89, 5462-5466 (1992)). Hence, a molecule capable of binding to a site in the A β molecule that is critical for fibril formation with an affinity higher than native A β should have reasonable chances to inhibit amyloid growth and maybe also specifically dissolve amyloid fibrils.


In conclusion, we have identified an A β sequence, KLVFF, which is required for amyloid fibril formation. The KLVFF peptide may serve as a model substance for the synthesis of non-peptide A β -ligands that interfere with the polymerization of A β molecules.

Previous studies suggested that amino acid residues within or close to A β -16-20 are important for the adoption of the correct β -pleated sheet structure of A β (18) and the proteolytic processing of its precursor (14).

We have now shown that this region harbors at least one binding sequence required for the polymerization of A β into amyloid fibrils. It was also demonstrated that short peptides incorporating A β -16-20 can function as ligands that bind to A β and inhibit the formation of amyloid fibrils. Since these peptide ligands are relatively small, they are amenable for identification of other organic molecules with similar functional properties. Non-peptide homologues of KLVFF should be useful as pharmacological drugs for the treatment of Alzheimer's disease in the future.

CLAIMS

1. A compound having the formula



5

in which

X' means any group or amino acid imparting to the compound of formula (I) the ability to bind to the KLVFF-sequence in amyloid β peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline;

Y' means any amino acid;

Z' means any non-acidic amino acid;

A' means a direct bond or an α -amino acid bonded at the carboxyl terminal of the α -carboxygroup or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of the α -carboxy group;

B' means a direct bond or an α -amino acid bonded at the α -nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α -nitrogen of the N-terminal α -amino acid;

R₁ is H or -CO-R₃ bonded at the α -amino group of A';

R₂ is H, -OR₄ or NR₅R₆, all bound to the α -carboxyl group of the α -carboxyterminal of B';

R₃ is a straight or branched carbon chain of 1-4 carbon atoms;

R₄ is a straight or branched carbon chain of 1-4 carbon atoms;


R₅ and R₆ independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are -(CH₂)_n-, where n is 4-5;

R₁ and R₂ together can form a hydrocarbon ring or heterocyclic ring; and

all the α -amino acids can be either D- or L-isomers; with the proviso that (I) is not Lys-Leu-Val-Phe-Phe.

2. A compound according to claim 1, which exhibits an ability to inhibit polymerization of amyloid β peptide.

3. A compound according to any one of claims 1-2, wherein all the amino acids are D-isomers.
4. A compound according to any one of the preceding claims, wherein Y' is Lys.
- 5 5. A compound according to claim 4, wherein Y' is Lys and Z' is Phe.
6. A compound according to any one of claims 1-3, wherein Y' is Phe.
7. A compound according to any one of the preceding claims, wherein X' is Val-Val.
- 10 8. A compound according to any one of the preceding claims, wherein R₁ is acetyl.
9. A compound according to any one of claims 1-8, wherein R₁ is H and/or R₂ is H.
- 15 10. Use of a compound of formula



in which

- 20 X' means any group or amino acid imparting to the compound of formula (II) the ability to bind to the KLVFF-sequence in the amyloid β peptide, or two amino acids imparting the same ability, but with the proviso that one is not proline;
- 25 Y' means any amino acid;
- Z' means any non-acidic amino acid;
- A' means a direct bond or an α -amino acid bonded at the carboxyl terminal of the α -carboxygroup or a di-, tri-, tetra- or pentapeptide bonded at the carboxyl terminal of
- 30 the α -carboxy group;
- B' means a direct bond or an α -amino acid bonded at the α -nitrogen or a di-, tri-, tetra- or pentapeptide bonded at the α -nitrogen of the N-terminal α -amino acid;
- R₁ is H or -CO-R₃ bonded at the α -amino group of A';
- 35 R₂ is H, -OR₄ or NR₅R₆, all bound to the α -carboxyl group of the α -carboxyterminal of B';

R₃ is a straight or branched carbon chain of 1-4 carbon atoms;

R₄ is a straight or branched carbon chain of 1-4 carbon atoms;

- 5 R₅ and R₆ independently are H, alkyl, cycloalkyl, aryl or substituted aryl or together are -(CH₂)_n-, where n is 4-5; R₁ and R₂ together can form a hydrocarbon ring or hetero-cyclic ring;

all the α-amino acids can be either D- or L-isomers;

- 10 for inhibition of polymerization of amyloid β peptide, as model substance for synthesis of amyloid β peptide-ligands for inhibition of polymerization of amyloid β peptide, as a tool for the identification of other organic compounds with similar functional
15 properties or as a ligand in PET (positron emission tomography).

11. Use according to claim 10, wherein all the amino acids of the compound are D-isomers.

12. Use according to any one of claims 10-11,
20 wherein Y' is Lys.

13. Use according to claim 12, wherein Y' is Lys and Z' is Phe.

14. Use according to any one of claims 10-11, wherein Y' is Phe.

- 25 15. Use according to any one of claims 10-14, wherein X' is Val-Val.

16. Use according to any one of claims 10-15, wherein R₁ is acetyl.

17. Use according to any one of claims 10-15,
30 wherein R₁ is H and/or R₂ is H.

18. A compound according to any one of claims 1-9 for use as a medicament.

19. Use of a compound according to any one of claims 1-9 for the manufacture of a medicament for
35 the treatment or prevention of amyloidosis.

20. Use of a compound according to any one of claims 1-9 for the manufacture of a medicament for

the treatment or prevention of Alzheimer disease associated with amyloidosis.


21. Use of a compound according to any one of claims 1-9 for the manufacture of a medicament for
5 the treatment or prevention of demens in patients with Down's syndrome.

22. Use of a compound according to any one of claims 1-9 for the manufacture of a medicament for the treatment or prevention of Hereditary cerebral
10 hemorrhage with amyloidosis (Dutch type).

23. Use of a compound according to any one of claims 1-9 for the manufacture of a medicament for the prevention of fibril formation of human amyloid protein.


15 24. A composition comprising a compound according to any one of claims 1-9 and optionally a ligand capable of binding or interacting with the compound according to formula I and a carrier.

20 25. A composition according to claim 24, which is adapted for injection or oral administration.



2/6

Fig. 2 A.







Fig. 2 B.

Fig. 2 C.



5/6

Fig. 2 D.





Fig. 3 A-B.



INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 96/01621

A. CLASSIFICATION OF SUBJECT MATTER		
IPC6: C07K 14/47, C07K 7/04 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
MEDLINE, WPI, CA, REG, EPOQUE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9508999 A1 (CITY OF HOPE), 6 April 1995 (06.04.95), page 3, line 26 - line 36, page 8, line 27 - page 9, line 17, SEQ ID No 5, 14, 15 --	1-25
X	EP 0584452 A1 (AMERICAN CYANAMID COMPANY), 2 March 1994 (02.03.94), SEQ ID No 7, 25, 27 --	1-25
X	WO 9419692 A1 (THE GENERAL HOSPITAL CORPORATION), 1 Sept 1994 (01.09.94), SEQ ID No 11 --	1-3,9-11, 17-25
P,X	WO 9634887 A2 (IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE), 7 November 1996 (07.11.96), claims 10, 11, 13 --	1-6
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
18 March 1997		26 -03- 1997
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Patrick Andersson Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 96/01621

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9414836 A1 (CENTOCOR, INC.), 7 July 1994 (07.07.94), claim 15 -- -----	1-4,8-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

04/03/97

International application No.

PCT/SE 96/01621

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO-A1-	9508999	06/04/95	EP-A-	0670731	13/09/95
			US-A-	5470951	28/11/95
EP-A1-	0584452	02/03/94	AU-B-	667895	18/04/96
			AU-A-	3835893	04/11/93
			CA-A-	2095421	02/11/93
			JP-A-	7132094	23/05/95
			NZ-A-	247499	26/04/96
			ZA-A-	9303084	24/11/93
WO-A1-	9419692	01/09/94	US-A-	5578451	26/11/96
WO-A2-	9634887	07/11/96	AU-A-	5654096	21/11/96
			GB-D-	9509263	00/00/00
			GB-D-	9607505	00/00/00
WO-A1-	9414836	07/07/94	NONE		